Intech Investment Management LLC Purchases 2,331 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 21.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,989 shares of the company’s stock after buying an additional 2,331 shares during the period. Intech Investment Management LLC’s holdings in Amphastar Pharmaceuticals were worth $630,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMPH. International Assets Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $11,070,000. Victory Capital Management Inc. raised its stake in shares of Amphastar Pharmaceuticals by 10.9% in the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after purchasing an additional 21,530 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $785,000. Granite Investment Partners LLC boosted its position in shares of Amphastar Pharmaceuticals by 12.7% during the second quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after buying an additional 44,744 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new position in shares of Amphastar Pharmaceuticals during the second quarter worth about $93,000. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $45.19 on Friday. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 15.06, a P/E/G ratio of 0.90 and a beta of 0.82. The stock’s fifty day moving average price is $47.83 and its two-hundred day moving average price is $44.55.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 3,000 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now directly owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This represents a 3.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This trade represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,533 shares of company stock valued at $1,378,252. 27.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler lowered their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.